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One of the biggest debates in modern cardiology regards the
relative merit of primary angioplasty versus pharmacologic
thrombolysis for the treatment of acute myocardial infarc-
tion (MI). Following a number of encouraging pilot studies,
the Primary Angioplasty in Myocardial Infarction
(PAMI-1) study in 1993 showed a clear benefit of primary
angioplasty over tissue plasminogen activator in reducing
death or MI (1). Simultaneously, the Zwolle and Mayo
Clinic groups published similar trials demonstrating a ben-
efit of primary angioplasty (2,3). A meta-analysis of the 10
such randomized trials through 1997 demonstrated a clear
and dramatic reduction in all cardiovascular end points
including death, MI, stroke and intracranial hemorrhage
(4). The relative reduction in mortality alone was 34% (from
6.5% for thrombolysis to 4.4% for primary angioplasty),
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indicating the potential of saving 2 lives for every 100
patients treated with primary angioplasty instead of throm-
bolysis. There was an even more dramatic in intracranial
hemorrhage, which was reduced from 1.1% for patients
treated with thrombolytic therapy to 0.1% for patients
treated with primary angioplasty. Based on these data,
primary angioplasty emerged as a superior therapy, at least
in the hospitals participating in these trials.
The next question was whether such excellent results
could be duplicated under “real world” conditions, given
concerns regarding more delayed time to treatment and lack
of operator experience in the “real world” as compared with
the selected hospitals that participated in the pivotal ran-
domized trials. Although initial comparisons in registry data
failed to show a benefit in patients treated with primary
angioplasty versus thrombolysis (5,6), the most recent com-
parisons within the large National Registry of Myocardial
Infarction (NRMI) show a clear benefit of primary percu-
taneous coronary intervention (PCI) (7). When results were
stratified based on the number of primary PCI procedures
performed per year at each participating hospital, patients
treated at the highest volume hospitals had the same degree
of mortality benefit (3.4% vs. 5.4%, p  0.001) seen in the
randomized trials. Even at intermediate volume hospitals—
two middle quartiles of volume defined as 17 to 48 primary
PCI procedures per year—showed a significant benefit of
primary angioplasty (4.5% mortality vs. 5.9% for thrombol-
ysis, p 0.001). While the lowest volume centers (perform-
ing 16 or fewer primary PCI procedures per year) showed no
mortality benefit, the total stroke rate was significantly lower
(0.4% vs. 1.1% for thrombolytic therapy). Preliminary data
now suggest that this benefit may also extend to community
hospitals that have initiated primary PCI programs despite
not offering elective PCI. The Cardiovascular Patient Out-
come Research Team (C-PORT) study evaluated 433
patients presenting to such community hospitals who were
randomized to on-site primary angioplasty versus thrombol-
ysis, demonstrating a lower rate of the primary end point of
death, MI or stroke for primary angioplasty at both six
weeks and six months (8). Thus, at hospitals that offer both
primary PCI and thrombolysis, primary PCI can be accom-
plished with superior results to thrombolysis, and is gener-
ally the treatment of choice for patients presenting there
with ST-segment elevation MI.
Although this addresses the issue of real world expertise,
the issue of prolonged time to reperfusion remains. In an
analysis of over 27,000 patients in NRMI Registry, an
increased door-to-balloon time was found to be significantly
associated with increased mortality (9). In this study, mor-
tality was between 40% and 60% higher for patients with
door-to-balloon times (between hospital arrival and the first
inflation of the angioplasty balloon) 2 h, even after
adjustment for differences in baseline characteristics. Thus,
a major emphasis has been placed on trying to increase
triage and execution efficiency and thereby reduce overall
door-to-balloon times at all hospitals performing primary
PCI. It also raises the real question of how to treat the
patient with an acute MI who presents to a hospital without
on-site primary PCI capabilities, since transfer to another
facility offering primary PCI would clearly introduce addi-
tional delay.
To address this matter, in this issue of the Journal, the
PAMI investigator group reports results of the Air-PAMI
study (10). In this trial, high risk patients with ST-segment
elevation MI (anterior MI, age 70 years, heart rate 100
beats/min or blood pressure 100 mm Hg or Killip Class 2
to 3), were randomized to either on-site thrombolytic
therapy (80% tissue plasminogen activator or recombinant
plasminogen activator) or transfer to another facility for
primary PCI. Although the study design was an excellent
one to resolve this contentious issue, slow patient accrual
over more than 3 years at 12 sites led to premature
termination of enrollment after entry of only 138 patients—
32% of the targeted sample size. Despite this limitation, the
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AIR-PAMI study has several important findings. As ex-
pected, the time to treatment was quite long for patients
transferred for primary angioplasty. Using a blend of ground
(79%) and helicopter (21%), transport times over the 32 
36 mile interhospital distance took only 26 min, but delays
in initiating the transfer added 43 min to the process, and
contributed importantly to the mean door-to-balloon time
of 155 min. No patients died or required cardiopulmonary
resuscitation during transfer, but estimated time to reper-
fusion was nearly an hour longer than that for thrombolytic
therapy (using a door-to-drug time of 51 min, and an
estimated time of 45 min from thrombolytic administration
to reperfusion). Despite this estimated delay to reperfusion,
the composite end point—death, MI or disabling stroke—
was reduced by 38% (from 13.6% for on-site thrombolysis
to 8.4% for primary PCI). Although this difference did not
reach statistical significance in the unadjusted analysis given
the smaller-than-planned sample size, there was clear ben-
efit when baseline differences were adjusted using a pre-
specified multivariate analysis which showed that the strat-
egy of transfer for primary angioplasty was associated with
reduction in the primary end point (odds ratio, 0.16; p 
0.03). Although it is not conclusive, this study provides
support for the overall strategy of transfer for primary
angioplasty in lieu of on-site thrombolysis.
We now have data from two related European studies.
The PRAGUE (PRimary Angioplasty in patients trans-
ferred from a General community hospital to specialized
PTCA Units, with or without Emergency thrombolysis)
compared three strategies: 1) on-site thrombolysis (as stud-
ied in Air-PAMI); 2) immediate transfer for primary
angioplasty; and 3) initial thrombolytic therapy followed by
transfer for emergency angioplasty (11). The lowest rate of
death, MI or stroke at 30 days was seen in the group
transferred for primary angioplasty (8%), compared to 23%
for on-site thrombolysis alone and 15% for patients treated
with both thrombolysis and primary angioplasty. The dom-
inant contributor to this benefit was a reduction in reinfarc-
tion in patients treated with primary angioplasty only (1%),
compared to 10% in patients treated by thrombolysis only,
and 7% for patients treated with both thrombolysis and
primary angioplasty. A much larger study, DANAMI-2,
compared transfer for primary PCI versus thrombolysis.
This trial was stopped early by the Data and Safety
Monitoring Committee, and results presented at the March
2002 meeting of the American College of Cardiology show
a significantly reduced incidence of death, recurrent infarc-
tion or stroke at 30 days (8.5 vs. 14.26, p  0.002) for
patients transferred from a community to a tertiary hospital
for primary PCI rather than receiving on-site thrombolytic
therapy (12).
Even as these important studies were underway, however,
important shifts have been taking place in PCI technique
adjunctive pharmacology. Stenting (rather than balloon
angioplasty) has become the dominant form of primary
PCI, although it was used in only 34% of the Air-PAMI
patients. In addition, many studies have suggested that
platelet glycoprotein IIb/IIIa receptor blockade is beneficial
during primary PCI. Indeed, one randomized trial of
coronary stenting with IIb/IIIa inhibition compared with
front-loaded tissue plasminogen activator showed a 66%
reduction in death, MI or stroke with the primary PCI
strategy (13), although the larger CADILLAC trial showed
minimal incremental benefit from routine IIb/IIIa blocker
administration at the time of primary stenting (14). Large-
scale trials of routine earlier initiation of IIb/IIIa receptor
blockade before primary PCI are underway.
Thus, the results of the Air-PAMI study are seen best in
the context of the ongoing evolution that is taking place in
primary PCI and its associated adjunctive therapies. In
particular, it appears that there may be benefit in prompt
and efficient transfer of patients from a community hospital
that does not offer primary PCI to a nearby one that does.
Conversely, an alternative model might be to regionalize
acute MI care services (akin to what has been done for major
trauma services). According to this model, patients found to
have ST-segment elevation on field 12-lead electocardio-
graphy would not necessarily be brought to the nearest
hospital. Instead had the community set up a network of
“cardiac centers” offering 24 h/7 days primary PCI, such
patients would have had suitable medical pretreatment (for
example, administration of aspirin, clopidogrel and IIb/IIIa
inhibition) initiated in the ambulance and be transferred
directly to the cardiac catheterization laboratory at such a
center, thereby avoiding a second ambulance trip and
minimizing time-to-reperfusion. Pilot studies of this strat-
egy, are just beginning in Florida and in Boston, but further
study will be needed before its role in the continued
refinement of reperfusion strategy for patients with acute
MI is established.
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